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On day 6 (ATN-Lia˜no score of 0.838; APACHE II of 23;
APACHE II risk of 45%), continuous veno-venous hemofil-
tration and dialysis (CVVHD) was initiated and maintained
for 3 days. Intermittent daily hemodialysis using a synthetic
(polysulfone) membrane was then introduced. Fourteen ses-
sions of hemodialysis were performed, and the blood urea and
serum creatinine levels were kept below 180 and 5 mg/dL,
respectively. Only one episode of hyperkalemia (5.8 mEq/L)
with acidosis (pH of 7.21 and plasma HCO3 of 14 mEq/L) was
observed. Total parenteral nutrition was administered through-
out this period. His urinary output dropped to 20 to 30 mL/h
after the introduction of hemodialysis and began to increase
(40 to 50 mL/h) after 10 days. During that period, weaning
from the ventilator was started and the hyperbaric oxygen
therapy was discontinued.
By day 26 after admission, his urinary output had reachedCASE PRESENTATION
110 mL/h and the serum creatinine had progressively decreased.
A 56-year-old man was admitted to the hospital with acute He was discharged from the hospital on day 32 with a serum cre-
suppurative appendicitis. A laparotomy was performed, and he atinine of 1.2 mg/dL and a creatinine clearance of 70 mL/min.
developed sepsis after the surgery. After seven days he was
transferred to the intensive care unit of the Escola Paulista
de Medicina with necrotizing fasciitis (Fournier’s syndrome), DISCUSSION
respiratory distress, and increased levels of serum creatinine Dr. Nestor Schor (Dean, Postgraduate Programs and(2 mg/dL). At admission he had fever (38C), normal blood
Research; and Professor of Medicine, Disciplina de Ne-pressure (140/90 mm Hg), normal urinary flow with a FENa of
frologia, Escola Paulista de Medicina, Universidade Fed-0.9%, and was under mechanical ventilation. That same day
eral de Sa˜o Paulo, Brasil): In the present patient, thean exploratory laparotomy revealed significant necrosis of the
abdominal wall and an intracavitary infection. A peritoneos- diagnosis of sepsis was readily made by the presence
tomy was performed. of one major criterion, necrotizing fasciitis (Fournier’s
Hemodynamic monitoring with a Swan-Ganz catheter re- gangrene), and two minor criteria: respiratory distress
vealed normal pulmonary capillary wedge pressure (16 mm Hg) and fever. Acute renal failure (ARF), as often occurs,
and a septic profile (high cardiac index and low systemic vascu-
complicated the clinical condition [1].lar resistance index). Despite a normal urinary output of 70 to
Hemodynamic monitoring revealed a hyperdynamic90 mL/h, the serum creatinine gradually increased to 5 mg/dL
pattern, with low systemic vascular resistance and highover the following 6 days. During this period he underwent two
cardiac output, both of which are characteristic of septicabdominal surgeries and daily hyperbaric oxygen therapy in a
2.5 atmosphere chamber, while receiving metronidazole, van- shock. The pulmonary capillary wedge pressure (PCWP)
comycin, and a third-generation cephalosporin. No aminogly- was normal at 16 mm Hg, although PCWP can be a mis-
coside antibiotic was administered. No bacteria or fungi were leading index of left-ventricular pre-load (defined as vol-
identified in blood, urine, or even in the abdominal secretions. ume). But sequential measurements of end-diastolic vol-
umes are not routinely available. Importantly, diastolic
dysfunction, a common feature of septic shock, is attrib-The Nephrology Forum is funded in part by grants from Amgen,
uted, at least in part, to an interstitial myocarditis thatIncorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
rated; and Bristol-Myers Squibb Company. is a classic acute inflammatory response characterized by
a polymorphonuclear cell infiltration and varying amountsKey words: lipopolysaccharide, endotoxin, endothelin, platelet activat-
of cellular tissue necrosis [2]. Therefore, the search foring factor, tumor necrosis factor, nitric oxide, ischemic preconditioning,
hyperkalemia. an ideal indicator of myocardial dysfunction in sepsis is
an ongoing and important issue. Troponin 1 has recently 2002 by the International Society of Nephrology
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been recognized as a promising tool for the identification kinase (IK) [10]. The subsequent release of NF-B from
IB results in the translocation of NF-B to the nucleus,of myocardial injury in sepsis [3].
Sepsis, especially septic shock, is one of the main where it binds to specific sequences in the promoter
regions of target genes. A large number of genes appearcauses of ARF. The prevalence of ARF in sepsis ranges
from 9% to 40% [4]. Lia˜no et al recently presented data to be targets of NF-B. These genes are responsible for
the coding and transcription of several cytokines and che-from the Madrid Acute Renal Failure Study Group [5]
indicating that sepsis caused acute tubular necrosis in mokines, for instance, tumor necrosis factor- (TNF),
platelet activating factor (PAF), leukotrienes/prostaglan-35% of patients in an intensive care unit (ICU) and 27%
of non-ICU patients. In a French multicenter study, ARF dins (LT/PGs), interferon , interleukin (IL)-1, IL-6, IL-8,
and IL-12. In the systemic circulation, these moleculeswas related to sepsis in 48% of the patients [6]. Also,
the mortality rate was higher in septic patients with ARF can cause hemodynamic imbalance and cell/organ dys-
function and can lead to apoptosis, necrosis, and death.than in nonseptic patients (73% vs. 45%). In a prospec-
tive study including a large number of patients with sepsis Recently it was shown that receptors of the “toll fam-
ily” play a major role in the induction of immune andand septic shock, the incidence of ARF was 19% in
sepsis, 23% in severe sepsis, and 51% in septic shock inflammatory responses [11]. The first receptor of the
toll family was identified in Drosophila as a component[7]. Using data from the General Hospital of the Univer-
sity of Sa˜o Paulo, Burdmann et al reported that 35% of a signaling pathway that controls polarity in fly em-
bryos. The sequence of the toll gene revealed that itof the cases of ARF resulted from sepsis, 33% from
hypovolemia, 32% from congestive heart failure, and encodes a transmembrane protein that has a cytoplasmic
domain similar to the mammalian interleukin-1–recep-27% from nephrotoxic agents (mainly antibiotics) [1].
The mortality rate reached 50% in patients with the tor; the transmembrane protein leads to the activation
of transcription factors of the NF-B family. Homologsmultiple organ dysfunction syndrome (MODS) in the
ICU, compared with a 7% mortality rate in patients in of Drosophila toll are referred to as toll-like receptors
(TLRs). The first human TLR to be characterized, TLR4,a general hospital [1]. The primary mediators of the
sepsis syndrome and its deadly complications are the activates the NF-B signaling pathway. Another protein,
the MD-2, is required for TLR4-mediated recognitionendotoxins.
Endotoxins are lipopolysaccharides (LPS) of the outer of LPS, forming a recognition complex of CD14, TLR4,
and MD-2. After this complex is activated, it recruitsmembrane of gram-negative bacteria. The effects of en-
dotoxin depend on the equilibrium between the cellular the adapter protein MyD88, which is associated with the
serine-threonine protein kinase interleukin-1–receptor–mediators released and their natural antagonists. The
effects also are influenced by the nature of the endotoxin associated kinase (IRAK). In turn, IRAK is phosphory-
lated and associated with the tumor necrosis factor–and by genetic factors. The marked heterogeneity of LPS
is responsible for the diversity of their biologic proper- associated factor 6 (TRAF-6) adapter protein. The
oligomerization of TRAF-6 activates a member of theties, for instance, the activation of complement, cytokine
production, toxicity, and resistance to antibiotics. Al- mitogen-activated protein kinase kinase kinase family
(MAP3K) that activates the IB kinase 1 (IK1) and 2though LPS of E. coli are the most frequent and impor-
tant endotoxins studied, other LPS from gram-negative (IK2) [11]. These kinases phosphorylate IB on serine
residues and release NF-B, which moves to the nucleus.bacteria also might participate in the septic syndrome.
Our understanding of the molecular events involved The mCD14 molecule can be released from the GPI
in the membrane and circulates in the serum (sCD14;in the recognition of LPS by target cells is incomplete,
but a key role for the CD14 receptor was established by Fig. 1). The sCD14 linked with LPS stimulates endothe-
lial and epithelial cells (including renal tubular cells).the finding that CD14-deficient mice are insensitive to
the effects of LPS [8]. Studies on the interaction of LPS The cells not only release cytokines and chemokines, but
also VCAM, ICAM, selectins, and MCP-1 (monocyteand other inflammatory mediators indicated that the first
step in the cascade is the binding of LPS to a specific chemoattractant protein-1) [12], which are responsible
for the adhesion of PMN cells and monocytes to endothe-soluble protein, the LPS-binding protein (LBP) (Fig.
1). The LPS-LBP complex interacts with the glycosyl- lial cells. These mediators also increase vessel permeabil-
ity, which leads to contraction of intravascular volumephosphatidylinositol (GPI)-anchored CD14 receptor in
the membrane (mCD14) of polymorphonuclear neutro- and hypotension. The alteration caused by these adhe-
sion molecules on the tubular epithelium leads to cellphil (PMN) cells, macrophages, and other cells such as
mesangial cells [9]. The interaction of the LPS-LBP com- detachment, resulting in tubular obstruction and cellular
necrosis. Data obtained in the ischemia/reperfusionplex with CD14 leads to phosphorylation of the complex
formed by the nuclear factor-B (NF-B), a member of model in the mouse showed high levels of renal ICAM-1
mRNA, and increased systemic levels of IL-1 and TNFthe Rel family of transcription factors (p50, p56, and
p65, among others), and its inhibitor (I-NF) via an IB one hour after ischemia/reperfusion. Protection of the
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Fig. 1. Mediators of cellular origin (see text for abbreviations).
glomerular filtration rate (GFR) was observed in ICAM-1 tures despite the shut-off of the initial pathophysiologic
stimulus.knockout mice as well as in neutrophil-depleted mice.
However, treatment of the latter with anti-ICAM-1 anti-
Pathophysiologic mediatorsbodies conferred no additional protection. Thus, ICAM-1
is a possible mediator of ischemic acute renal injury, The clinical forms of acute renal failure vary from
acute tubular necrosis (ATN) to bilateral cortical necro-acting via the potentiation of neutrophil-endothelial cell
interaction [13]. The activation of NF-B in peripheral sis. A large body of evidence from experimental models
and human endotoxemia studies suggests that various in-blood mononuclear cells of patients with sepsis is in-
creased in patients who die when compared with survi- flammatory mediators and neuro-endocrine mechanisms
are involved in the pathogenesis of ARF in sepsis. Thevors [14].
Lipopolysaccharide also can activate soluble factors interplay of these pathways results in severe renal hypo-
perfusion, a major factor in the development of ARF.(that is, cytokines and chemokines in circulation (Fig. 1)
and initiate the septic cascade. The same overall mecha- However, non-hemodynamic responses to endotoxin
contribute importantly to the acute renal dysfunction.nism, operative in PMNs, also is observed in mesangial
cells. Many factors block NF-B activation, such as glu- Lugon and co-workers in our laboratory observed a
decrease in both total and single-nephron GFR in endo-cocorticoids, cyclosporine, angiotensin-converting en-
zyme inhibitor (ACEI), lovastatin-like drugs, etc. [15]. toxemic rats that was mediated by high renal vascular
resistance (RVR) and decreased renal plasma flow (RPF;It is possible that the effect of ACEI in delaying the pro-
gression of sepsis-induced acute renal failure is caused Fig. 2) [16]. The impressive increase in RVR was a conse-
quence of a high afferent arteriolar resistance. The ele-by a reduction of NF-B formation. The presence of an
amplifying loop, given a positive feedback further pro- gant studies by Cohen and co-workers showed that LPS
alone, in a serum-free, artificially perfused rat kidney,ducing inflammatory and other molecules, could explain
the maintenance of a low GFR via contraction of mesan- did not modify GFR or tubular function, and suggested
that extrarenal mediators are required [17]. In a similargial cells and interference with other glomerular struc-
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Fig. 2. Effects of lipopolysaccharides (LPS) on renal (A) and glomerular (B) hemodynamics: Role of angiotensin and prostaglandin systems.
Abbreviations are: CAPT, captopril; INDO, indomethacin; GFR, glomerular filtration rate; RPF, renal plasma flow; TRVR, total renal vascular
resistance; SNGFR, single-nephron glomerular filtration rate; QA, glomerular plasma flow; P, transglomerular hydraulic pressure; RA, afferent,
and RE, efferent, arteriolar resistances; Kf, glomerular ultrafiltration coefficient. P  0.05 after versus before LPS infusion; P  0.05 versus LPS
alone.
experimental model of isolated perfused kidney, Linas animal models of sepsis treated with anti-PAF antibody,
suggesting an important role of PAF in septic shock [25].and colleagues observed that the simultaneous perfusion
Endothelin-1 (ET), a peptide with highly potent vaso-with LPS and PMN cells (previously activated with LPS
constrictor activity, reduces GFR and RPF as a conse-and formyl peptides) caused a striking decrease in GFR,
quence of its effects on afferent and efferent glomerularand suggested a necessary interaction for the induction of
arterioles. Tumor necrosis factor, vasopressin, angioten-ARF [18]. They also suggested that PMN cell activation
sin II, and PAF are among the factors that stimulate thereleases both oxygen metabolites and elastase. Here I
release of ET-1 [4]. In addition to circulating ET-1, lo-will review briefly the most important mediators of the
cally synthesized ET-1 in the kidney by various types ofhemodynamic response.
renal cells, including mesangial and endothelial cells, actsTumor necrosis factor (TNF), a pleiotropic cytokine,
as an autocrine and paracrine factor. In an elegant proto-mediates a broad spectrum of host responses to endotox-
col, Kon and Badr showed that the intrarenal administra-emia. It is released from circulating and resident (mesan-
tion of anti-ET-1 antibody blunted the renal hypofiltra-gial) cells following stimulation by LPS [19, 20]. Levels
tion observed during a systemic infusion of LPS [26].of TNF are elevated in patients with septic shock and
The inducible nitric oxide (NO) synthase (iNOS),are correlated with the severity of sepsis and mortality
through NO generation, has been implicated in the he-rate [21]. In turn, TNF stimulates a cascade of vasoactive
modynamic alterations observed in sepsis, mainly induc-and inflammatory mediators that participate in the septic
tion of vasodilation [4]. The expression of iNOS is in-
syndrome [4] and in the renal response to LPS. Local
duced by TNF and IL-1 in macrophages, vascular smooth
release of TNF from mesangial cells following stimula- muscle, and mesangial cells. On the other hand, local
tion by LPS induces apoptotic death of glomerular endo- NO regulates efferent arteriolar tone, thus influencing
thelial cells [20]. Passive immunization to TNF protects the maintenance of renal hemodynamics. Nitric oxide
against the renal effects of LPS in rhesus monkeys [22]. inhibition during endotoxic injury increases proteinuria,
Platelet activating factor (PAF) is another mediator decreases GFR, and leads to a marked glomerular
released by glomerular endothelial and mesangial cells thrombosis, suggesting an important protective role of
in response to LPS [4]. The glomerular hemodynamic this mediator in septic ARF [27]. Weight and colleagues
effects of PAF include increases of both afferent and have observed a bimodal response to NOS inhibition in
efferent arteriolar resistances that cause reduction of the the ischemia-reperfusion model, with an early ameliora-
glomerular plasma flow and intraglomerular hydraulic tion but a late exacerbation of the oxidative damage;
pressure; these changes, coupled with an associated de- these data suggest that although the early burst of NO
crease in Kf, produce a substantial decline of GFR [23]. can have a cytotoxic action, NO might exert an overall
The levels of PAF in blood and urine are elevated in cytoprotective effect [28]. Acute L-arginine administra-
septic patients and correlate with the severity of ARF tion is beneficial in in-vivo renal ischemia but harmful
in isolated tubules made hypoxic and reperfused [29].[24]. An impressive reduction in mortality is seen in
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Oral supplementation or intravenous infusion of L-argi- the coagulation and fibrinolysis cascade, thereby causing
intrarenal coagulation [39]. Moreover, neutrophil activa-nine supports a protective effect of NO on renal function
in a number of nephrotoxic models of ARF such as those tion, which is high in patients with ARF and sepsis,
resulted in reduction of GFR [40]. As I mentioned, ininduced by contrast media [30], cyclosporine A (CsA)
[31], glycerol [32], uranyl nitrate [33], and gentamicin the isolated perfused kidney, the GFR-reducing effect
of the LPS was only evident in the presence of endotoxin-[34].
During ischemia, antisense oligonucleotides to iNOS, activated neutrophils [18].
In summary, by interacting with circulating and resi-but not the knocking out of the iNOS gene, attenuated
the LPS-induced fall in GFR [35]. The latter effect was dent cell types, such as monocytes/macrophages and en-
dothelial, PMN, and mesangial cells, endotoxin stimu-due to an attenuation of the tubular injury [36] and
suggests cytotoxic effects of the NO produced via iNOS lates the release of inflammatory cytokines and other
vasoactive substances. These mediators coupled withduring the ARF. Thus, the available data indicate a vari-
able role of NO in ARF, and the ultimate (cumulative) neuroendocrine factors and the coagulation/fibrinolysis
cascades, which are activated by endotoxin, lead to pro-effect will depend on the experimental model, the po-
tency of inhibitor/stimulator of the NO system, and the found alterations of renal function in sepsis and ARF.
Because the various cytokines and vasoactive com-stage of ARF studied.
Thromboxane A2 (TxA2) is the major vasoconstrictor pounds discussed earlier induce tissue ischemia, it is in-
teresting to examine preconditioning situations relatedproduct of the cyclo-oxygenase pathway causing declines
in RPF and GFR due to preferential constriction of the to ARF. Ischemic preconditioning (IPC) is a general
term used to describe maneuvers that increase toleranceafferent arterioles [4]. Lipopolysaccharide is a potent
stimulator of TxA2 synthesis in renal cortex, and vari- of a tissue to a prolonged, potentially lethal, period of
ischemia. Although the beneficial effects of IPC wereous reports have provided evidence for a role of TxA2-
induced vasoconstriction in models of experimental sep- first observed in the myocardium, it is now clear that
IPC also protects the brain, liver, lung, and several othersis through the release of PAF [37]. Selective antagonists
afford protection against renal ischemia. Data from our organs, including the kidney. Although the different
steps involved in this phenomenon are far from fullylaboratory showed that indomethacin, a nonspecific inhib-
itor of prostaglandins and thromboxanes, had a markedly elucidated, the currently favored hypothesis is that IPC
initiates, via receptor stimulation, activation of phospho-protective effect on glomerular hemodynamics in endo-
toxemic rats, suggesting that TxA2 might play an impor- lipase C and/or D, production of the second messenger
diacylglycerol (DAG), and the resultant activation andtant role in LPS-induced ARF (Fig. 2) [16].
Leukotrienes (LTs) are also implicated in the patho- subcellular redistribution of one or more of the known
isoforms of protein kinase C (PKC) to the membrane;physiology of sepsis-induced ARF, as they are highly po-
tent vasoconstrictor eicosanoids [4]. These compounds the latter events potentially trigger a kinase cascade that
ultimately culminates in the phosphorylation of the final(LTC4, LTD4, and LTE4) are produced by the 5-lipoxygen-
ase enzyme pathway and are related to the slow-reacting effector agents [41].
Differential display polymerase chain reaction and dif-substances of anaphylaxis. Their vasoconstrictive prop-
erty causes a reduction of RPF and GFR mainly due to ferential cDNA library screening techniques have been
used to identify differentially expressed genes after renalpre-glomerular vasoconstriction and associated reduc-
tion in Kf, the latter likely indicating mesangial cell con- blood flow cessation of 30 to 60 minutes. These tech-
niques have led to the identification of genes that codetraction [38]. Leukotriene levels are increased during
sepsis, and use of LT antagonists minimizes the effects for proteins apparently essential for either renal tubular
cell death, such as Siva (a pro-apoptotic protein), or forof intravenous LPS administration, including the acute
renal dysfunction [37]. cell regeneration, such as calcyclin and the receptor for
activated C kinase (RACK1) [reviewed in 42]. UsingA number of other important humoral vasoactive me-
diators also are implicated in septic ARF, including the an IPC renal model, Gomes, Cancherini, and Rebouc¸as
suggested that the mechanisms of IPC must include up-renin-angiotensin system (RAS), the kallikrein-kinin
system, atrial natriuretic factor, IL-1, adenosine, and cat- regulation of proteins involved in cytoskeleton organiza-
tion, such as tropomyosin 4, caldesmon, actin depolymer-echolamines. The role of the RAS on LPS-induced ARF
is indicated in Figure 2, which shows that captopril re- izing factor, or proteins related to both preservation and
recovery of the functional folding of these proteins, suchduced the adverse effects of LPS on renal hemody-
namics. as HSP70, a heat shock protein, and CCT, a member
of the chaperone family, whose mRNA levels were in-Beyond the hemodynamic adversity, the aforemen-
tioned mediators also contribute to the acute renal dys- creased by approximately 50% (unpublished data). They
also observed an up-regulation of proteins related tofunction by non-hemodynamic responses to endotoxin,
including activation of the complement system, and of oxidative phosphorylation, such as NADH-ubiquinone
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tients. These indices, used mainly in ICUs, are useful tools
for quality control, allocation of resources in the ICU,
comparison of different units, and adequate randomiza-
tion in clinical trials. In recent years, the APACHE II
score has been the most widely used prognostic score
index in the ICU. Although it has been validated only
in ICU patients, it has been used for non-ICU patients
with ARF [46]. The APACHE II score has been used
to randomize patients with ARF at the time of initiation
of dialysis in clinical trials as well [47]. We investigated
the differences between ICU and non-ICU patients with
ARF, and sought to determine whether the APACHE II
score can be used as a prognostic score index for non-ICU
patients (abstract, Fernandes et al, J Am Soc Nephrol
10:140A, 1999). We compared the performance of the
APACHE II score with that of the acute tubular necro-
sis-individual severity score (ATN-ISS), a specific score
for the population with ARF [48]. Data were collected
from 205 ARF patients at the Hospital Sa˜o Paulo, a uni-
Fig. 3. Total glomerular filtration rate (GFR) in virgin, pregnancy versity-based, non-profit, tertiary hospital. APACHE II(Preg), and abortion (Abort) groups before and after infusion of lipo-
scores were calculated at the time of hospital admissionpolysaccharide (LPS). *P  0.05 verus before LPS.
(AP-1), at referral to the nephrologist (AP-2), and at ini-
tiation of dialysis (AP-3). The ATN-ISS score was ob-
tained only once, when the patient was referred to thereductase and cytochrome c oxydase subunit II, which
might be important for fast recovery or preservation of nephrologist. Data were similar between ICU and non-
the mitochondrial complex I after ischemic insult. ICU patients for AP-1, AP-2, and ATN-ISS. Thus, the
An important event related to both preconditioning APACHE II score collected at hospital admission or at
and recovery is the synthesis of heat shock proteins (HSP; the time of referral to the nephrologist and the ATN-
stress proteins) in response to a mild stress, a phenome- ISS score can be used as a severity-of-illness score for
non that allows cells to adapt to gradual changes in their non-ICU patients (Fig. 4). The discrimination capacity of
environment and to survive under potentially lethal con- APACHE II and ATN-ISS (area under the ROC curves
ditions [43, 44]. Heat shock proteins alone or in combina- in Fig. 4) was similar. Thus, when using APACHE II, the
tion with chaperones are involved in several cellular pro-
chance for detecting those patients who were likely to diecesses, such as correction of the folding and assembling
was similar for both ICU (AUC	0.66) and non-ICUof intracellular proteins, transport and degradation of pro-
(AUC	0.78) patients. Therefore, these results also sup-teins, as well as preservation and restructuring of the
port the utilization of APACHE II for non-ICU patients.cytoskeleton [44]. The presence of various HSP (for ex-
The time of collection of data for the APACHE II scoreample, HSP70, HSP72, HSP25/27) with a specific distri-
was investigated, and scores obtained at the time of refer-bution pattern along the nephron segments, both in mes-
ral to the nephrologist were better than scores obtainedangial and epithelial cells, indicates a potential role for
HSP not only in initiation and maintenance but also in at hospital admission or at the initiation of dialysis. Thus,
recovery from injury, including endotoxic insult [44]. ARF per se seems to be an important determinant of prog-
Using a model of abortion induced by RU-486 with nosis. The ATN-ISS score was a better predictor of death
or without LPS administration, Boim and coworkers in than was the nonspecific APACHE II score. In another
our laboratory showed that LPS was more effective in Brazilian study, Batista evaluated different prognostic in-
decreasing GFR in pregnant than in virgin rats (Fig. 3) dices, including the ATN-ISS score, the APACHE II score,
[45]. However, after the induction of abortion, the LPS the long injury score (LIS), and the number of organ fail-
effect increased. This finding suggested a sensitization
ure (NOF) score, in ARF patients at the ICU of Sa˜o Ra-to the toxic effects of LPS in this clinical situation. This
fael Hospital, a teaching hospital in the city of Salvadorpotentiation might explain the high morbidity and mor-
[49]. In contrast with the study at Hospital Sa˜o Paulo,tality rates of septic abortions.
the APACHE II and ATN-ISS scores showed similar dis-
Prognosis criminative power. This fact illustrates the need for study-
ing the discrimination and calibration of these prognosticIn the clinical setting, prognostic score indices often
have been used in the prediction of outcomes of ARF pa- scores for each hospital.
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Fig. 4. Discrimination analysis (ROC curves) of APACHE II and ATN-ISS indices obtained at the time of referral to the nephrologist of ICU
and non-ICU patients. AUC, area under the curve.
Clinical issues to change recovery and mortality rates. A negative result
also was observed with ANF (anaritide) in another trialTrials. Only a few multicenter clinical trials have at-
of ARF patients [53]. These results emphasize the impor-tempted to change the high mortality rate observed in
tance of the development of multitargeted therapeuticpatients with ARF and the septic syndrome. One of them
strategies because of the multifactorial nature of thewas based on the observation that insulin-like growth
pathophysiology of sepsis-associated ARF.factor-I (IGF-I) increased RPF and GFR in normal rats,
Hyperkalemia. In today’s patient, the only episode ofin normal adult humans, and in patients with chronic
hyperkalemia was largely ascribed to reduced potassiumrenal failure [50]. Also, IGF-I buttressed the recovery
excretion, a frequent indication for initiating dialysis. Theof GFR, healing the affected nephrons and reducing
decrease in potassium excretion observed during ARF isthe mortality rate in animals after ischemic, toxic, or
predominantly caused by a low tubular flow rate due to aendotoxic ARF [51]. In a multicenter trial, with a pro-
reduction in GFR and accompanying epithelial cell dam-spective, double-blind, randomized design, patients with
age. Under normal conditions, tubular epithelial cells re-ARF of all types received rhIGF-I versus placebo [52].
spond to variations in serum levels of potassium and/orBaseline values of GFR, urinary volume, BUN, serum
plasma aldosterone with adequate potassium secretioncreatinine, and albumin were similar between groups, as
in cortical collecting ducts (CCD), increasing or reducingwas the need for dialysis. Thirty-seven percent of the
renal potassium excretion. However, during renal insuf-patients receiving rhIGF-I and 35% of those receiving
placebo had septic ARF. Treatment with IGF-I failed ficiency, even the viable cells might not be able to secrete
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potassium properly. The density and the activity of potas- Several methods of dialysis are available for renal re-
placement therapy (RRT). Continuous RRT (CRRT),sium-secreting channels in the apical membrane of CCD
cells might be involved in this deficiency. Rabb and co- the most frequently used approach in the intensive care
unit, is potentially indicated for the removal of inflam-workers showed that the changes in potassium handl-
ing in ischemic ARF are associated, at least in part, with a matory mediators; most studies in critically ill patients
with sepsis and ARF have demonstrated the presencesuppression of the potassium secretory channel (ROMK1)
mRNA [54]. On the other hand, a reduction in proximal of such mediators in the ultrafiltrate [58]. However, the
process itself involves induction of cytokines and com-sodium reabsorption can increase sodium delivery and
potassium secretion in the CCD. The deficiency in so- plement activation, so elimination of natural inhibitors
of pro-inflammatory substances also can occur. To ad-dium reabsorption along the nephron is related to several
sodium transporter mechanisms, including the redistri- dress this issue, Vriese and colleagues performed contin-
uous venovenous hemofiltration (CVVH) with an AN69bution of Na/K/ATPase, mainly in proximal tubules, and
the down-regulation of sodium transporters, including membrane in septic patients with ARF [59]. They ob-
served a decline in some cytokines during the first hourNa/K/ATPase, Na/H exchanger (NHE3), Na/K/2Cl co-
transporter, and Na/Cl cotransporter [55]. Although the of hemofiltration, but a partial recovery occurred after
12 hours. Their study suggested a beneficial effect ofhigh sodium concentration in the tubular fluid and/or
the high levels of aldosterone would tend to augment CVVH, especially if the membrane is frequently re-
placed and a high ultrafiltration rate is used.potassium secretion in the CCD, this process is impeded
by the suppression of the ROMK1 channels. Moreover, Cardiovascular instability is the most common compli-
cation of dialysis, especially in critically ill patients whothe colonic K/H/ATPase mRNA in the distal nephron
is overexpressed during ischemic/reperfusion injury [56]; have established ARF. In this setting, intermittent hemo-
dialysis increases the risk of hemodynamic instability.the resultant increased hydrogen secretion prevents bi-
carbonate wasting, but the increased potassium reab- However, the slow nature of CRRT allows for a slow
rate of ultrafiltration with a lower impact on blood pres-sorption contributes to the hyperkalemia.
Although hyperkalemia is a life-threatening complica- sure. In general, CRRT is indicated for hemodynamically
unstable and fluid-overloaded patients; intermittent he-tion of ARF, safe levels of serum potassium are often
achieved in ARF, even with extremely low GFR. Redis- modialysis is better for patients who are hemodynami-
cally stable. An individualized approach should be usedtribution of potassium into cells is one potential adaptive
mechanism for reducing serum potassium levels. More- for each patient to optimize management of ARF. De-
spite significant advances in technology, the effect ofover, intestinal potassium excretion can substantially in-
crease in patients with renal insufficiency. The channel- CRRT on overall patient outcome remains unclear. No
study has showed an increased rate of survival withinducing factor (CHIF), a molecule expressed in distal
parts of the nephron and intestine and regulated by po- CRRT as opposed to HD in patients with ARF [60].
In patients with chronic renal failure, the use of dialyz-tassium intake and aldosterone, respectively, might play
a role in potassium homeostasis in ARF. In fact, expres- ers with unsubstituted cellulose membranes results in
complement and leukocyte activation with the genera-sion of CHIF mRNA is dramatically decreased in the
kidney and increased in the colon in a model of acute tion and release of cytokines by peripheral blood mono-
nuclear cells (PBMCs) [61] and the production of reac-tubular necrosis induced by glycerol injection [57]. Thus,
the deficiency in renal potassium excretion during ARF tive oxygen species by neutrophils [40]. It thus has been
hypothesized that in the setting of ARF, production ofis a result of a complex interaction among several factors.
The level of serum potassium concentration depends on these inflammatory mediators during dialysis with un-
substituted cellulose membranes leads to a worsening ofthe extent to which each of these factors is altered in a
particular patient as well as on changes in redistribution the inflammation within the kidney, a prolonged need
for dialysis, and a worse outcome.of potassium into cells and intestinal potassium excre-
tion. Despite the fact that the molecular basis for the possi-
ble benefit of more biocompatible membranes has not
Dialysis been studied in humans, a number of clinical trials have
been conducted in the last decade. The first clinical trialsBecause the risk of death in patients with ARF in-
creases with the need for dialytic support, many issues comparing intermittent hemodialysis with cellulose mem-
branes and synthetic membranes suggested that the syn-regarding the use of renal replacement therapy have
been investigated. These include timing of initiation, thetic membranes produced improved outcomes [62].
However, more recent studies have not confirmed thesemodality, type of dialyzer membrane, and dose of dial-
ysis. The type of dialyzer membrane used during inter- findings (abstracts, Gastaldello et al, J Am Soc Nephrol
7:1447, 1996; Albright et al, J Am Soc Nephrol 99:197A,mittent hemodialysis (IHD) has received the most atten-
tion. 1998; Jorres et al, J Am Soc Nephrol 9:212A, 1998). In
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one study (abstract, Karsou et al, J Am Soc Nephrol 10: increase in the use of intravenous lipid emulsions in such
patients.286A, 1999), a meta-analysis of the clinical trials compar-
ing outcomes of patients with ARF dialyzed with cellu- There is broad agreement that nitrogen administration
is necessary and beneficial in critically ill patients. Pa-lose/cellulose-derived membranes or synthetic membranes
was performed. In the final analysis, the risk ratio for tients with ARF have urea appearance rates ranging
from 7.5 to 18.0 g nitrogen/day [67]. For such highlydeath was 0.92 (95% confidence interval, 0.76 to 1.13, not
significant) comparing cellulose-derived with synthetic catabolic patients, however, no optimal level of protein
intake has been established that avoids or reduces themembranes. Another recent study addressed the biologic
basis of the hypothesis that bioincompatible membranes need for renal support. Chronic renal failure patients,
whose protein catabolism is severalfold lower than thatcould increase inflammatory mediators in patients with
ARF [48]. In a crossover study, the authors examined the of ARF patients, benefit from parenteral formulas con-
taining essential amino acids as the sole protein sourceeffect of the dialyzer membrane type on cytokine synthe-
sis by PBMCs, superoxide release by neutrophils, and and demonstrate reduced urea production rates and
lower dialysis requirements. The biologic rationale ofapoptosis of neutrophils. There was no impact of dialyzer
biocompatibility on the synthesis of TNF or IL-10 by these formulas is that the synthesis of nonessential amino
acids retains the nitrogen molecules that would otherwisePBMCs, superoxide release by neutrophils, or neutrophil
apoptosis. This held true regardless of the initial dialyzer be excreted. Hence, urea generation is reduced. In the
ARF patient, however, the use of essential amino acidsassignment. Furthermore, there was no correlation be-
tween dialysis adequacy (measured by single pool Kt/V) has not been effective [68] because of the very high
protein catabolic rate.and post-dialysis cellular responses. Therefore, in this
population of very sick, often septic, patients with ARF, Nutritional management in ARF also is influenced by
the modality of renal support. Many nutrients, includingbioincompatibility of dialysis membranes seemed to play
a minor role in the cellular responses monitored. free amino acids, are lost during CRRT and must be
replaced by parenteral nutrition. In CVVH, for instance,In summary, although initial studies suggested that bio-
incompatible membranes could worsen the outcomes of amino acid loss can be as high as 4 to 7 g/day [69].
ARF patients during dialysis, the accumulated data from
Recoveryclinical trials suggest that their role is probably insignifi-
cant. Despite the technologic advances in renal replace- Most patients who survive an episode of ARF partially
or totally recover their renal function. In today’s case,ment therapy techniques, recent data indicate that the dia-
lytic management of ICU patients also can rely on a more the patient was discharged from the hospital with a serum
creatinine level of 1.2 mg/dL and a creatinine clearanceconventional option. Indeed, adequate ultrafiltration and
good metabolic control were achieved with continuous of 70 mL/min. During the recovery phase, the progres-
sive improvement of glomerular filtration and tubularperitoneal dialysis, even in hypercatabolic patients [ab-
stract; Pecoits-Filho et al, Perit Dial Int 20(Suppl 1):S72, function gradually increases urinary volume. This com-
plex phenomenon depends on a series of events that2000]. Peritonitis (10%), hypernatremia, and high serum
bicarbonate levels were the main complications, and all allows the anatomic and functional recovery of the renal
tissues. The process involves the regeneration of thewere adequately controlled.
injured but still viable cells and the removal and replace-
Parenteral nutrition ment of the dead cells that detach from the tubular base-
ment membrane toward the lumen as a result of necroticEven while receiving parenteral nutrition, patients
with sepsis as the cause of ARF who have a dysfunction- and apoptotic mechanisms. Initially, dedifferentiation
takes place and marginal cells near the denuded tubularing gastrointestinal tract have a mortality rate of 80%
to 90% [63]. These patients are in substantial negative regions acquire an epithelial aspect; then they migrate
and multiply in an attempt to completely re-epithelializenitrogen balance as a result of their high protein catabolic
rates. An important issue is the amount of calories that the renal tubule [70]. This process involves dynamic
changes in the extracellular matrix, the expression andshould be administered to ARF patients. Furthermore,
the accuracy of measurements of energy expenditure in distribution of cytoskeleton, and the membrane proteins.
In many aspects, this process recapitulates the cellularsuch patients is complicated [64]. Therefore, calorimetric
methods are often preferred for the assessment of energy mechanisms involved in renal embryogenesis [71].
The recovery phenomenon depends, at least in part,expenditure in ARF-MODS patients [65]. Another im-
portant issue relates to the composition of the nonpro- on the participation of growth factors, which, through
their autocrine, paracrine, and endocrine actions, cantein component of the diet. Evidence from two decades
ago suggests that in sepsis there is a shift in fuel prefer- stimulate cellular migration and proliferation in addition
to promoting tubulogenesis, thereby re-establishing theence to lipids [66]. This information, obtained from ex-
perimental and human studies, has led to a progressive integrity of the tubular epithelium [72–74, 75]. Renal
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cells exposed to these growth factors or to a harmful Dr. Schor: The physiologic and metabolic manifesta-
tions of septic shock include severe hypotension, myocar-event (ischemia or toxins) express a group of immediate
early genes in a similar way [76]. Additionally, genes dial dysfunction, organ hypoperfusion, and lactic acido-
sis. The last of these is mainly a consequence of cellularthat express HSP (HSP70 and HSP25, for instance) par-
ticipate in the recovery phase from LPS injury [77, 19]. hypoxia due to alterations in the microcirculation. How-
ever, it is possible that LPS per se, or via pro-inflamma-The exogenous administration of growth factors, espe-
cially EGF, IGF-I, and HGF, proved to be beneficial in tory cytokines, such as TNF or IL-1
, causes mitochon-
drial dysfunction that aggravates lactic acidosis. In recentvarious experimental ARF protocols by reducing injury,
accelerating recovery of renal function, mitigating catab- years mutations in human mitochondrial DNA have
been described that could potentiate lactic acidosis inolism, and improving the survival of the treated animals
[74, 78]. Recently, we demonstrated in a model of in- septicemia [80]. Remember that drugs can affect mito-
chondrial metabolism, mainly nucleoside analogs (anti-vitro hypoxia that HGF, but not EGF or IGF-I, could
diminish injury, improve cell viability, and reduce apo- retroviral drugs), and their administration in septic pa-
tients could exacerbate lactic acidosis.ptosis of renal tubular cells (abstract, Dura˜o et al, J Am
Soc Nephrol 9:587A, 1998). Unfortunately, however, the Dr. Miguel Cendoroglo (Associate Professor of Ne-
phrology, Escola Paulista de Medicine-UNIFESP, Sa˜ouse of IGF in humans with ARF failed to show any
beneficial effects in one carefully controlled study [52]. Paulo): What is your opinion about the importance of
the “toll-like receptor 4” in the specificity of innate im-
munity?
QUESTIONS AND ANSWERS
Dr. Schor: The recent discovery of the toll-like recep-
Dr. Nicolaos E. Madias (Executive Academic Dean, tor, mainly the Tlr4, has contributed to our understand-
Tufts University School of Medicine, Boston, Massachu- ing of the afferent limb of the innate immune response.
setts, USA): Exciting information has appeared recently As you know, the toxic effects of LPS are indirect; macro-
on the strong association of the TNF2 polymorphism of phages are the pivotal cells in the signaling mechanisms
the TNF promoter with susceptibility to septic shock and resulting biologic responses [11]. Toll receptors,
and death due to septic shock [75]. Could you please which are plasma membrane receptors on macrophages,
comment on the potential implications of this and similar essentially function as LPS sensors; they “sense” the
polymorphisms of mediators of the sepsis syndrome? presence of LPS, cause activation of NF-B, and trigger
Dr. Schor: Yes. The multicenter study you mentioned the pro-inflammatory response. It is possible that even
looked for a polymorphism of TNF promoter and dis- modest perturbations of Tlr4 (including altered quantity
closed that the frequency of the TNF2 allele is strongly or post-translational modifications) and/or related mole-
associated with susceptibility to septic shock and with a cules profoundly transform the response to LPS. This is
high mortality rate [75]. Although this study found an the beginning of a new and important field of research
association between the TNF2 allele and mortality, it of the septic syndrome.
failed to detect a correlation with plasma TNF concen- Dr. Madias: How specific and selective is the down-
tration. As I mentioned, despite experimental data indi- regulation of the transport molecules that you mentioned
cating that the administration of anti-TNF antibody or in acute renal failure?
antibody against TNF receptors protects animals from Dr. Schor: Renal ischemia in rats significantly down-
lethal effects caused by LPS, one rigorous clinical study regulates Na transporters along the nephron and aqua-
did not show improvement in survival rates with the use porins in the collecting duct with no alteration in other
of anti-TNF antibody [79]. I believe that future clinical membrane proteins; this finding suggests selectivity of
trials should target a number of mediators since it is clear ischemia-induced ARF on transport molecules [55]. It
that ARF induced by sepsis is a multifactorial disease. is unknown whether other toxic or septic insults induce
Genetic polymorphisms of various cytokines might well the same kind of down-regulation. However, as LPS are
be involved in the development or outcome of the sepsis localized on plasma membranes of the apical microvilli
syndrome. and in the labyrinth of the lateral intercellular spaces,
Dr. Gerhard Malnic (Professor of Physiology and alterations in other transporters also might occur.
Biophysics, Instituto de Cieˆncias Biolo´gicas, University Dr. Luis Yu (Associate Professor of Nephrology, Uni-
of Sa˜o Paulo, Sa˜o Paulo, Brasil): Sepsis is one of the versity of Sa˜o Paulo): Is there any difference in gram-
leading causes of lactic acidosis, and tissue hypoperfusion positive and gram-negative sepsis-induced ARF regard-
and hypoxia are involved in the development of this ing incidence and outcome?
complication. Of the many steps in the cascade of factors Dr. Schor: There are no conclusive data on this issue,
you described, which are important for the development although increased incidence and mortality of ARF due
of lactic acidosis? Are there pathogenetic factors besides to gram-positive sepsis compared with gram-negative
sepsis have been reported [81].hypoperfusion?
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Dr. Omar Da Rosa Santos (Chairman, Internal Medi- anticytokine strategies, have failed in the treatment of
cine, University of Rio de Janeiro-UNI-Rio, Rio de Ja- the sepsis syndrome. Do you see a role for extracorporeal
neiro, Brasil): Oxygen therapy in a hyperbaric chamber adsorptive therapies for removal of microbial mediators
has been claimed to be valuable in the treatment of of sepsis, such as polymyxin B–linked polymers?
several clinical conditions. What is the clinical indication, Dr. Schor: As I mentioned, the problem with these
if any, for starting hyperbaric oxygen therapy, chiefly in nonspecific therapies is that they can remove both anti-
the setting of acute renal failure? and pro-inflammatory mediators. Polymyxin-B-linked
Dr. Schor: Although there are no specific indications polymers have been used in Japan, and several authors
for ARF, some clinical conditions related to ARF could have claimed that they could improve outcome in septic
be treated by hyperbaric oxygen therapy, such as necro- patients. Polymyxin B indeed can remove LPS from the
tizing infection of soft tissues, muscles, and fascia, espe- blood and decrease its effect on cytokine generation by
cially when gaseous gangrene is present. However, early mononuclear cells. However, the problem is that these
and aggressive surgical exploration is important to re- polymers would need to be used in the early phase of
move the necrotic tissue, reduce compartmental pres- sepsis. Also, in spite of the availability of this technique
sure, and obtain material for analysis and culture before for more than 10 years, no controlled trial has been
initiation of hyperbaric treatment. Crush and compart- published. Therefore, I remain skeptical about this tech-
mental syndromes, acute ischemic lesions, and refractory nology.
osteomyelitis, which frequently are associated with ARF, Dr. David Machado (Associate Professor of Nephrol-
also are indications for hyperbaric oxygen treatment. ogy, University of Sa˜o Paulo): You said that the best
Hyperbaric oxygen therapy for grafted skin, burns, and renal replacement therapy is the one you know how to
radiation-induced tissue damage can be useful. Finally, do best. But sometimes, the optimal treatment is the one
poisoning by cyanide or carbon monoxide, gaseous em- that is available. What is the role of peritoneal dialysis
bolus, and diving decompressive disease are other indica- in acute renal failure?
tions for hyperbaric oxygen therapy. Dr. Schor: Dr. Noronha’s group has shown that using
Dr. Madias: Given the several potential utilities of continuous peritoneal dialysis in an intensive care unit
renal replacement therapy in the acute renal failure of can produce metabolic control as well as adequate ultra-
sepsis, what are your thoughts on the timing of its initia- filtration, even for hypercatabolic patients [abstract, Pec-
tion? oits-Filho et al, Perit Dial Int 20(Suppl 1):S72, 2000]. As
Dr. Schor: It is clear to me that there is a moderate I mentioned earlier, peritonitis (10%), hypernatremia,
removal of inflammatory mediators during continuous and high serum bicarbonate were the main complications
chronic renal replacement therapy in septic patients, par-
but were adequately controlled. Therefore, peritoneal
ticularly when high volumes of ultrafiltration are achieved.
dialysis can be utilized as an efficient method for renalSome clinicians have advocated its use in the early phase
replacement, including in acute situations.of septic ARF, but anti- as well as pro-inflammatory me-
Dr. Madias: Can you discuss the appropriate dosediators are removed, and the net effect is not known yet.
of intermittent hemodialysis or continuous therapies inOn the other hand, the beneficial effect of high convec-
acute renal failure?tive clearances also could be due to optimal control of
Dr. Schor: The literature contains little informationuremic toxicity.
about this topic. Some recent retrospective studies haveDr. Emmanuel Burdmann (Associate Professor of
suggested a beneficial effect of higher doses of dialysis.Nephrology, Sa˜o Jose´ do Roi Preto Medical School, Sa˜o
However, no prospective study has addressed this ques-Paulo): Would you please comment on the possible role
tion. In 1997, during the ASN meeting in San Antonio,of vancomycin in the development of ARF in this pa-
Dr. Schiffl presented interesting results of an interimtient?
analysis of an ongoing prospective clinical trial compar-Dr. Schor: Vancomycin administration has been asso-
ing patients assigned to daily hemodialysis with patientsciated with ARF due to acute tubular necrosis indepen-
assigned to alternate-day dialysis. The analysis showeddently of the concomitant use of other nephrotoxic drugs
better survival in patients treated with more frequentor hemodynamic alterations. So vancomycin might have
dialysis. This study has not yet been published, however.played a role in precipitating the ARF in this case. It is
Ronco et al made a similar observation and recom-interesting to note that experimental and clinical data
mended an increase in the rate of ultrafiltration to im-suggest that vancomycin nephrotoxicity can be reduced
prove mortality rates [82].with the concomitant use of cilastatin, imipemen, or tei-
Dr. Paulo Benigno Batista (Associate Professor ofcoplamide. At any event, it is important that one adjust
Nephrology, Escola Baiana de Medicina e Sau´de Pu´blica,the vancomycin dose during CRRT.
Salvador, Brasil): Considering the weight of non-renalDr. Madias: You mentioned that a number of immu-
notherapeutic approaches, for example, anti-LPS mAb, variables in the prognosis of death in patients with ARF,
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mediators in sepsis and renal failure. Kidney Int 53(Suppl 66):S38–do you think that it is important to develop an ARF-
S42, 1998
specific prognostic index for these patients? 10. Karin M, Delhase M: The IB kinase (IKK) and NF-B: Key
Dr. Schor: Yes. The more general prognostic indices elements of proinflammatory signalling. Immunology 12:85–98, 2000
11. Medzhitov R, Janeway C: Advances in Immunology: Innate im-do not fit well for ARF. It has been suggested that the
munity. N Engl J Med 343:338–344, 2000ATN-ISS [48] index offers better discrimination than 12. Wang Y, Rangan GK, Goodwin B, et al: Lipopolysaccharide-
other indices commonly used in ICUs. For general prog- induced MCP-1 gene expression in rat tubular epithelial cells is
nuclear factor-B dependent. Kidney Int 57:2011–2022, 2000nosis, the APACHE II score appears to better predict
13. Kelly KJ, Williams WW Jr, Colvin RB, et al: Intercellular adhe-death in patients with ARF at the time of evaluation by sion molecule-1–deficient mice are protected against ischemic renal
the nephrologist than at the time of ICU admission. injury. J Clin Invest 97:1056–1063, 1996
14. Arnalich F, Palomero EG, Lo´pez J, et al: Predictive value ofDr. Batista: What do you think about developing and
nuclear factor B activity and plasma cytokine levels in patientsvalidating at local, regional, and global levels a specific with sepsis. Infect Immun 68:1942–1945, 2000
prognostic index for ARF, independent of the therapeu- 15. Massy ZA, Guijarro C, O’Donnell MP, et al: The central role of
nuclear factor-B in mesangial cell activation. Kidney Int 56(Suppltics, for instance, mechanical ventilation, dialysis, etc.?
71):S76–S79, 1999Dr. Schor: Considering the relevance of these indices,
16. Lugon JR, Boim MA, Ramos OL, et al: Renal function and glomer-
we are looking to develop a specific index for our patients ular hemodynamics in male endotoxemic rats. Kidney Int 36:570–
575, 1989in Brasil. Such an indicator would be able to evaluate
17. Cohen JJ, Black AJ, Werthein SJ: Direct effects of endotoxinand compare patients with ARF and provide a prognos-
on the function of the isolated perfused rat kidney. Kidney Int
tic index for patients and groups of patients treated in 37:1219–1226, 1990
18. Linas SL, Whittenburg D, Parsons PE, Repine JE: Mild renalICUs with distinct technologic abilities.
ischemia activates primed neutrophils to cause acute renal failure.
Kidney Int 42:610–616, 1992Reprint requests to Dr. N. Schor, Disciplina de Nefrologia, Escola
Paulista de Medicina, Rua Botucatu´ 740, 04023-900 Sa˜o Paulo, Brasil. 19. Baud L, Oudinet JP, Bens M, et al: Production of tumor necrosis
E-mail: nestor@nefro.epm.br factor by rat mesangial cells in response to bacterial lipopolysaccha-
ride. Kidney Int 35:1111–1118, 1989
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